Maury Raycroft Analyst PerformanceAnalyst at Jefferies Financial GroupMaury Raycroft is a stock analyst at Jefferies Financial Group focused in the medical sector, covering 26 publicly traded companies. Over the past year, Maury Raycroft has issued 23 stock ratings, including buy and hold recommendations. While full access to Maury Raycroft's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Maury Raycroft's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings42 Last 8 YearsBuy Recommendations75.61% 31 Buy RatingsCompanies Covered26 Unique Companies Ratings Distribution41RatingsDistribution of strong buy, buy, hold, and sell ratings by Maury Raycroft.RatingPercentageCount Strong Buy0.0%0 ratings Buy75.6%31 ratings Hold24.4%10 ratings Sell0.0%0 ratingsOut of 41 total stock ratings issued by Maury Raycroft at Jefferies Financial Group, the majority (75.6%) have been Buy recommendations, followed by 24.4% Hold.Best & Worst CallsBest Call0000.0%XENEAug 2017Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%KPTIApr 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ96.2% of companies on NASDAQ25 companiesNYSE3.8% of companies on NYSE1 companyMaury Raycroft, an analyst at Jefferies Financial Group, currently covers 26 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical25 companies96.2%Manufacturing1 company3.8%Maury Raycroft of Jefferies Financial Group specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE16 companies61.5%MED - DRUGS3 companies11.5%PHARMACEUTICAL PREPARATIONS3 companies11.5%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES1 company3.8%MED INSTRUMENTS1 company3.8%MED PRODUCTS1 company3.8%LARGE CAP PHARMA1 company3.8% Maury Raycroft's Ratings History at Jefferies Financial Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCOAGHemab Therapeutics5/26/2026Initiated Coverage$25.89$39.00Buy$0.0000.00% ROICOAGHemab Therapeutics5/26/2026Initiated Coverage$27.84$39.00Buy$0.0000.00% ROITNGXTango Therapeutics5/14/2026Downgrade$25.51$27.00Hold$0.0000.00% ROICRBPCorbus Pharmaceuticals5/12/2026Lower Price Target$11.43$33.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals3/16/2026Reiterated Rating$313.41$330.00Hold$0.0000.00% ROIDTILPrecision BioSciences3/13/2026Reiterated Rating$5.67$19.00Buy$0.0000.00% ROIDNTHDianthus Therapeutics3/9/2026Set Price Target$79.23$98.00Buy$0.0000.00% ROITNGXTango Therapeutics3/5/2026Reiterated Rating$16.80$18.00Buy$0.0000.00% ROICMPXCompass Therapeutics3/5/2026Reiterated Rating$5.53$9.00Buy$0.0000.00% ROITYRATyra Biosciences2/3/2026Boost Price Target$31.02$43.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. DNTHDianthus Therapeutics2/2/2026Boost Price Target$52.96$81.00Buy$0.0000.00% ROIMREOMereo BioPharma Group12/30/2025Downgrade$0.29Hold$0.0000.00% ROIRAREUltragenyx Pharmaceutical12/30/2025Lower Price Target$19.72$63.00Buy$0.0000.00% ROICELCCelcuity12/2/2025Boost Price Target$98.49$134.00Buy$0.0000.00% ROIAUPHAurinia Pharmaceuticals11/7/2025Upgrade$13.95$21.00Buy$0.0000.00% ROIOPKOPKO Health10/30/2025Reiterated Rating$1.46$1.60Hold$0.0000.00% ROIALNYAlnylam Pharmaceuticals10/30/2025Lower Price Target$449.56$549.00Buy$0.0000.00% ROIKZRKezar Life Sciences10/17/2025Downgrade$4.17$7.00Hold$0.0000.00% ROIKODKodiak Sciences9/22/2025Initiated Coverage$12.97$15.00Buy$0.0000.00% ROITVTXTravere Therapeutics9/10/2025Set Price Target$27.31$35.00$0.0000.00% ROIVALNValneva8/25/2025Set Price Target$9.08$14.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals7/7/2025Boost Price Target$323.82$384.00Buy$0.0000.00% ROICRDFCardiff Oncology6/24/2025Initiated Coverage$3.16$3.50Hold$0.0000.00% ROICRBPCorbus Pharmaceuticals3/11/2025Lower Price Target$6.86$53.00Buy$00.0000.00% ROICMRXChimerix3/5/2025Reiterated Rating$8.46$8.50Hold$0.0000.00% ROICMPXCompass Therapeutics2/10/2025Boost Price Target$3.90$8.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
